Cadrenal Therapeutics (CVKD) Income from Continuing Operations (2022 - 2026)
Cadrenal Therapeutics (CVKD) posted Income from Continuing Operations of 2734829.0 for Q3 2024, down 13.86% sequentially from 2401910.0 in Q2 2024, and down 53.94% YoY from 5937146.59 in Q4 2023.
Cadrenal Therapeutics (CVKD) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Cadrenal Therapeutics has reported Income from Continuing Operations for 3 years, with the latest figure at 2734829.0 in Q3 2024.
- Quarterly Income from Continuing Operations fell 53.94% year-over-year to 2734829.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was 7944543.0 (up 19.59% YoY) and the FY2023 annual result came in at 8357086.0, down 24.47% from the prior year.
- Income from Continuing Operations slipped to 2734829.0 in Q3 2024 per CVKD's latest filing, from 2401910.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 172602.0 in Q1 2022 and troughed at 5008739.0 in Q1 2023.
- A 3-year average of 1770197.55 and a median of 1663744.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations tumbled 2801.9% in 2023, then jumped 66.78% in 2024.
- Over 3 years, Income from Continuing Operations stood at 1094073.0 in 2022, then retreated by 4.57% to 1144060.0 in 2023, then sank by 139.05% to 2734829.0 in 2024.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 2734829.0, 2401910.0, and 1663744.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Cadrenal Therapeutics | 4.59 Mn | 2.19 Mn | - | -3.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.33 Mn |
| Jun 30, 2025 | -3.86 Mn |
| Sep 30, 2024 | -2.73 Mn |
| Jun 30, 2024 | -2.40 Mn |
| Mar 31, 2024 | -1.66 Mn |
| Dec 31, 2023 | -1.14 Mn |
| Sep 30, 2023 | -1.78 Mn |
| Jun 30, 2023 | -2.00 Mn |
| Mar 31, 2023 | -5.01 Mn |
| Dec 31, 2022 | -1.09 Mn |
| Sep 30, 2022 | -986,332.00 |
| Jun 30, 2022 | -488,793.00 |
| Mar 31, 2022 | -172,602.00 |